Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000563

Drug Information
NameNeostigmine
SynonymsSpectrum_001061; KBioGR_000623; AC1L1I7G; 59-99-4; ZINC00001792; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; NINDS_000198; CAS-114-80-7; IDI1_000165; KBio1_000198; nchembio.188-comp33; DivK1c_000165; Prostigmin; CID4456; 51-60-5 (methyl sulfate); Lopac0_000816; UNII-3982TWQ96G; SPBio_002515; AB00053807; Neostigmine (BAN); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; KBio2_004109; BPBio1_000634; Synstigmin; NINDS_000165; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- (9CI); STL058953; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; sulfonatooxymethane; InChI=1/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1; IDI1_000198; KBio1_000165; Vagostigmin; NCGC00015730-01; HSDB 3921; DivK1c_000198; KBio2_006677; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-; BRD-K18922609-004-04-1; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); CHEBI:7514; HMS2089A22; Neostigmine [BAN]; Prestwick2_000468; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium; NCGC00015730-04; NCGC00021658-03; SPBio_001276; Eustigmine; Spectrum5_001234; Prostigmin (TN); Prostigmine; NCGC00163240-01; Intrastigmina; BRN 3615946; LS-18452; bmse000762; Vagostigmine; C07258; Lopac-N-2001; NCGC00015730-03; Prestwick3_000468; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; D08261; NCGC00015730-08; Neostigminum; CCRIS 3079; NEOSTIGMINE; Prozerin; KBioSS_001541; BSPBio_000576; [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; NCGC00015730-02; Prestwick1_000468; KBio2_001541; 114-80-7 (bromide); Juvastigmin; ALWKGYPQUAPLQC-UHFFFAOYSA-; Neostigmine omega; Eustigmin; Syntostigmine; Spectrum4_000072; Prestwick0_000468; DB01400; Spectrum2_001278; m-Trimethylammoniumphenyldimethylcarbamate; Neostigmin
Trade NameProstigmin; Vagostigmin
IndicationMyasthenia gravis
[ICD9: 358.0   ICD10: G70.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-
5H3/q+1
InChIKeyALWKGYPQUAPLQC-UHFFFAOYSA-N
Canonical SMILESCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C    
Therapeutic ClassParasympathomimetics
CAS NumberCAS 59-99-4
FormulaC12H19N2O2
PubChem Compound IDCID 4456.
PubChem Substance IDSID 9467.
SuperDrug ATC IDN07AA01; S01EB06
SuperDrug CAS ID000059994;
TargetAcetylcholinesteraseInhibitor[2][3]
Ref 1News for Pharma Mondial Pharmaceuticals Ltd (TR|Turkey) To Reference
Ref 2Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. To Reference
Ref 3Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543